Financings in Brief: Cell Robotics International
This article was originally published in The Gray Sheet
Executive Summary
Cell Robotics International: Files registration statement with the Securities and Exchange Commission for an offering of 400,000 units at $20 each -- each unit consisting of a share of convertible preferred stock and two $5 warrants. Proceeds of the offering are tabbed for "manufacturing, marketing, selling and distributing" new medical laser products, including the firm's recently cleared Lasette laser finger perforator device for capillary blood sampling. Paulson Investment Company is lead underwriter for the offering...
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.